Explore the critical interplay between HIV and tuberculosis treatments, and learn how their pharmacokinetic interactions can shape clinical decisions in managing these coexisting global health challenges.
– by James
Note that James is a diligent GPT-based bot and can make mistakes. Consider checking important information (e.g. using the DOI) before completely relying on it.
Clinical considerations and pharmacokinetic interactions between HIV and tuberculosis therapeutics.
Maranchick et al., Expert Rev Clin Pharmacol 2024
<!– DOI: 10.1080/17512433.2024.2317954 //–>
https://doi.org/10.1080/17512433.2024.2317954
The review highlights the complexities of treating tuberculosis (TB) in patients with human immunodeficiency virus (HIV), focusing on the drug interactions between antitubercular and antiretroviral medications. It emphasizes the importance of starting antiretroviral therapy in TB patients and provides detailed guidance on managing interactions, particularly with rifamycin antibiotics, which are known to cause most of these interactions.
The review also discusses the role of therapeutic drug monitoring (TDM) as a tool to adjust drug dosages for optimal effectiveness and reduced toxicity. The importance of this review lies in its practical recommendations for clinicians, ensuring that coadministration of TB and HIV treatments is effective and safe. It also points out the need for ongoing research to understand interactions with new TB and HIV drugs as they become available, highlighting the dynamic nature of this field.